Last Close
12.89
Jul 31 • 3:59 PM ET Dollar change-0.86 Percentage change(-6.25%)
Aftermarket Close
13.14
Aftermarket • 7:34 PM ET Dollar change+0.25 Percentage change(1.94%)
Index
RUT
Market Cap
439.47M
Enterprise Value
455.95M
Income
-21.57M
Sales
99.53M
Book/sh
0.43
Cash/sh
1.58
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
209
IPO
Apr 22, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
4.42
P/B
30.24
P/C
8.14
P/FCF
-
EV/EBITDA
-
EV/Sales
4.58
Quick Ratio
4.35
Current Ratio
5.38
Debt/Eq
4.88
LT Debt/Eq
4.73
Option/Short
Yes / Yes
EPS (ttm)
-0.65
EPS next Y
-0.37
EPS next Q
-0.22
EPS this Y
0.86%
EPS next Y
43.31%
EPS next 5Y
30.03%
EPS past 3/5Y
30.02% 8.43%
Sales past 3/5Y
29.99% 19.44%
EPS Y/Y TTM
21.86%
Sales Y/Y TTM
18.06%
EPS Q/Q
5.21%
Sales Q/Q
-2.02%
Insider Own
23.42%
Insider Trans
-0.31%
Inst Own
73.71%
Inst Trans
0.42%
ROA
-20.63%
ROE
-111.38%
ROIC
-26.07%
Gross Margin
78.29%
Oper. Margin
-16.84%
Profit Margin
-21.67%
SMA20
-17.87%
SMA50
-19.07%
SMA200
-14.61%
Trades
Shs Outstand
33.91M
Shs Float
26.11M
52W High
19.60 -34.23%
52W Low
7.56 70.45%
Volatility
6.19% 5.66%
ATR (14)
0.87
RSI (14)
29.60
Beta
1.93
Rel Volume
1.73
Avg Volume
191.76K
Volume
332,031
Perf Week
-12.96%
Perf Month
-18.26%
Perf Quarter
-23.55%
Perf Half Y
-15.86%
Perf YTD
-16.52%
Perf Year
51.47%
Perf 3Y
210.60%
Perf 5Y
-39.48%
Perf 10Y
-
Prev Close
13.75
Price
12.89
Change
-6.25%
Date Action Analyst Rating Change Price Target Change
Jul-23-26Initiated Mizuho Outperform $22
May-28-25Initiated H.C. Wainwright Buy $18
Jan-21-25Initiated UBS Buy $17
Mar-14-24Upgrade Wells Fargo Equal Weight → Overweight $16 → $20
Jan-30-24Initiated Leerink Partners Outperform $22
Nov-10-23Initiated Cantor Fitzgerald Overweight $11
Aug-24-23Upgrade Morgan Stanley Underweight → Equal-Weight $5 → $6
Feb-22-23Initiated Lake Street Buy $10
Apr-06-22Initiated Wolfe Research Outperform $13
Jan-19-22Downgrade Wells Fargo Overweight → Equal Weight $11
Jul-28-26 04:01PM
May-29-26 08:05AM
08:00AM
May-28-26 11:29AM
11:29AM
11:29AM Loading…
11:29AM
May-13-26 08:30AM
01:02AM
May-12-26 04:30PM
04:05PM
May-11-26 11:45AM
09:20AM
Apr-29-26 04:05PM
Apr-27-26 07:30AM
Apr-10-26 04:05PM
11:40AM Loading…
Mar-10-26 11:40AM
11:39AM
11:21AM
Mar-05-26 04:30PM
Mar-04-26 12:01AM
Mar-03-26 06:02PM
05:35PM
04:36PM
04:05PM
Mar-02-26 07:19AM
Feb-25-26 12:15PM
10:00AM
Feb-24-26 10:00AM
Feb-20-26 04:30PM
Feb-12-26 05:35PM
07:30AM Loading…
Jan-13-26 07:30AM
Dec-31-25 09:00AM
Dec-17-25 08:00AM
Dec-08-25 08:00AM
Dec-02-25 08:01AM
Nov-24-25 08:00AM
Nov-05-25 12:04AM
Nov-04-25 06:20PM
05:17PM
04:05PM
Nov-03-25 08:04AM
Oct-22-25 08:00AM
Aug-28-25 08:00AM
Aug-13-25 03:13AM
Aug-12-25 05:25PM
04:35PM
04:05PM
Aug-11-25 09:35AM
Aug-07-25 05:40PM
Aug-06-25 05:45PM
Aug-05-25 08:25AM
Aug-01-25 07:30AM
Jul-29-25 04:05PM
Jul-15-25 07:40AM
Jun-24-25 04:05PM
Jun-17-25 01:35PM
Jun-04-25 04:09PM
May-29-25 02:48PM
May-28-25 11:50AM
10:45AM
May-27-25 12:48PM
08:00AM
May-15-25 08:06AM
May-14-25 12:56PM
03:15AM
May-13-25 05:25PM
04:23PM
04:05PM
08:50AM
May-12-25 05:15PM
09:33AM
May-09-25 08:20AM
May-08-25 06:15PM
May-05-25 05:30PM
Apr-14-25 04:05PM
Apr-08-25 08:00AM
Apr-03-25 08:00AM
Apr-02-25 04:05PM
Mar-26-25 08:00AM
Mar-05-25 06:49AM
02:09AM
Mar-04-25 04:24PM
04:05PM
Mar-03-25 09:15PM
04:05PM
07:14AM
Feb-21-25 05:13AM
Feb-20-25 04:05PM
Feb-19-25 04:05PM
Feb-18-25 04:05PM
Feb-14-25 08:12AM
06:33AM
Feb-13-25 04:34PM
Feb-03-25 04:05PM
Jan-28-25 05:15PM
Jan-22-25 05:32AM
Jan-08-25 04:05PM
Dec-25-24 12:00PM
Dec-18-24 04:05PM
Dec-12-24 04:05PM
NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.
CEOMr. Joel D. Becker
Chief Financial OfficerMr. Patrick F. Williams
Chief Medical OfficerDr. Martha J. Morrell M.D.
Chief of Operations & DevelopmentMr. Dylan St. John
Head of Investor RelationsMr. Scott R. Schaper
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Morrell MarthaCHIEF MEDICAL OFFICERDec 15 '25Sale15.9725,000399,25049,964Mar 04 04:43 PM
MARTHA J MORRELLOfficerDec 15 '25Proposed Sale16.1925,000404,750Dec 15 04:26 PM